Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Study of the Efficacy and Safety of ACP-196 in Subjects With Relapsed/Refractory CLL and Intolerant of Ibrutinib Therapy

NCT02717611 is registered in ClinicalTrials.gov with Acerta Pharma BV as lead sponsor.

NCT NCT02717611
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02717611 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Study of the Efficacy and Safety of ACP-196 in Subjects With Relapsed/Refractory CLL and Intolerant of Ibrutinib Therapy
Lead sponsor
Acerta Pharma BV
Phase
Phase 2
Overall status
Active, not recruiting
Start date
March 8, 2016
Completion date
June 6, 2026
Enrollment
60 (actual)
Sites
23

Conditions

As the registry lists them; a condition with its own page is linked.

chronic lymphocytic leukemia